| Latest Omrix Biopharmaceuticals News Headlines | | Date | Time | Source | | | 12/27/2008 | 10:08AM | PRNUS | Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
NEW BRUNSWICK, N.J., Dec. 27 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE:JNJ) today announced that stockholders of Omrix Biopharmaceuticals, Inc. (NASDAQ:OMRI) ("Omrix") tendered approximately 16,749,152 shares of Omrix common stock, including approximately 1,293,924 shares subject to guaranteed delivery procedures... More...>> |
| 12/19/2008 | 5:42PM | PRNUS | Johnson & Johnson Extends Tender Offer for Omrix Biopharmaceuticals, Inc.
NEW BRUNSWICK, N.J., Dec. 19 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE:JNJ) today announced it has extended its previously announced cash tender offer, through its wholly-owned subsidiary, Binder Merger Sub, Inc., for all outstanding shares of common stock of Omrix Biopharmaceuticals, Inc. (NASDAQ:OMRI) until... More...>> |
| 12/11/2008 | 5:40PM | PRNUS | Johnson & Johnson Announces Receipt of Israeli Antitrust Approval for Acquisition of Omrix
NEW BRUNSWICK, N.J., Dec. 11 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE:JNJ) today announced that the Israeli General Director of the Antitrust Authority has approved Johnson & Johnson's proposed acquisition of Omrix Biopharmaceuticals, Inc. (NASDAQ:OMRI), under the Restrictive Trade Practices Law 5748-1988 of... More...>> |
| 11/25/2008 | 12:38PM | PRNUS | Johnson & Johnson Begins Tender Offer to Acquire Omrix
NEW BRUNSWICK, N.J., Nov. 25 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE:JNJ) is commencing today, through a new wholly-owned subsidiary, Binder Merger Sub, Inc., a cash tender offer to purchase all outstanding shares of common stock of Omrix Biopharmaceuticals, Inc. (NASDAQ:OMRI). Johnson & Johnson reported... More...>> |
| 09/18/2007 | 8:00AM | PRNUS | Peptimmune Appoints Fredric Price as Chairman and Reorganizes its Board of Directors
CAMBRIDGE, Mass., Sept. 18 /PRNewswire/ -- Peptimmune, Inc. a privately held biotechnology company, announced that Fredric D. Price has been appointed Executive Chairman of the Board of Directors. Mr. Price brings more than 30 years of biotechnology and pharmaceuticals industry experience to the company, including... More...>> |
| 07/05/2006 | 8:30AM | PRNUS | Symphony Medical Announces Initiation of Phase II Multi-Center Clinical Trial for Biologic Therapy to Prevent Post-Operative At
Study Intended to Validate Efficacy and Move Novel Technology Closer to Commercialization
LAGUNA HILLS, Calif., July 5 /PRNewswire/ -- Symphony Medical, Inc., a developer of new non-destructive biologic and biopolymer therapies to treat atrial fibrillation and other cardiac abnormalities, announced today patient enrollment... More...>> |
|